Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Mar 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a condition called transthyretin cardiac amyloidosis (ATTR-CA), which affects the heart and is often underdiagnosed. Researchers are looking into how many people are affected by this disease and how it progresses over time. This condition can lead to heart failure, where the heart struggles to pump blood effectively. The trial is particularly focused on patients who have been diagnosed with ATTR-CA while receiving care in internal medicine departments between 2013 and 2023.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of ATTR-CA. Unfortunately, people with other types of amyloidosis or those who do not wish for their data to be used for research cannot participate. Participants can expect that their medical information will be reviewed to help improve understanding and treatment of this condition. It’s important to note that while the survival rates for patients with ATTR-CA are improving, there is still much work to be done to better diagnose and treat this disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Sujet majeur (≥18 ans)
• • Diagnostic d'amylose à TTR suite à une hospitalisation en médecine interne aux HUS entre 01/01/2013 au 31/12/2023.
• Exclusion Criteria:
• • Subject (and/or their legal representative, if applicable) who has expressed their opposition to the reuse of their data for scientific research purposes.
• • Type of amyloidosis other than ATTR after review of the medical record (immunological assessment, imaging assessment, expert report).